



#### **Key Indices Update**

Indices	Close	Change (%)
Nifty	25,763.35	0.167
Sensex	83,978.49	0.057
Midcap	60,287.40	0.777
Smallcap	18,513.40	0.727

### Trend Strength Indicator

Nifty 50 Stocks above	NSE Advance /
200 EMA	Decline
37	1796 <b>/1313</b>

### Key Data

Data	Current	Previous
Dow Jones	47,254.6	47,562.8
U.S. Dollar Index	99.99	99.80
Brent Crude (USD/BBL)	64.77	65.00
US 10Y Bond Yield (%)	4.12	4.08
India 10Y Bond Yield (%)	6.54	6.59

#### Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	58120.95	0.607
NIFTYAUTO	26846.70	0.147
NIFTYENERG	36448.60	0.487
NIFTYFINSR	29731.95	0.877
NIFTYFMCG	56150.80	لا0.10
NIFTYIT	35660.65	0.1424
NIFTYMEDIA	1539.00	0.047
NIFTYMETAL	10651.00	0.377
NIFTYPHARM	22444.95	1.227
NIFTYREALT	970.25	2.407

Nov 04, 2025

### **Fundamental**

Refer Page 02

#### Stock for Investment

Stock Name	Sector	*CMP (₹)	^TP (₹)	Upside
HDFCLIFE	Life Insurance	747	870	16.5%

\*CMP as on November 03

### **Top News**

- + Nippon Life India Asset Management (NAM India) reported a strong Q2 FY26 performance, marked by its highest-ever quarterly Operating Profit of ₹4.19 bn . The company also achieved the fastest growth among the Top-10 AMCs in H1 FY26. NAM India's market share reached its highest point since June 2019 at 8.51% . The Board declared an Interim Dividend of ₹9.00 per share.
- + Sumitomo Chemical India reported a challenging Q2 due to heavy rainfall, impacting agrochemical consumption. Despite this, H1 sales grew 9% YoY, & profit grew 11%. Q2 consolidated revenue was ₹930 Cr, slightly down YoY, with gross margins at 43.1%. H1 revenue reached ₹1,987 Cr.

#### **Technical**

Refer Page 03-04

- Nifty held steady on Monday, with the Nifty 50 closing nearly flat at 25,763.35, up 0.13%, indicating continued consolidation after a strong October rally.
- + The index opened on a subdued note and remained range-bound throughout the session amid mixed global cues.
- + Sectorally, the action was split realty, pharma, and financials registered decent gains, while IT and FMCG lagged behind.
- + Technically, Nifty is expected to see further consolidation, with critical support placed around 25,600.
- + Amid this setup, we continue to recommend a selective approach, focusing on sectors showing relative strength, and preferring large-cap and large mid-cap stocks for long trades while maintaining moderate position sizes amid global uncertainty.
- + Stock of the day LUPIN





### **Fundamental**

### Top **News**

01

Nippon Life India Asset Management (NAM India) reported a strong Q2 FY26 performance, marked by its highest-ever quarterly Operating Profit of ₹4.19 bn. The company also achieved the fastest growth among the Top-10 AMCs in H1 FY26. NAM India's market share reached its highest point since June 2019 at 8.51%. The Board declared an Interim Dividend of ₹9.00 per share.

- 02
- Sumitomo Chemical India reported a challenging Q2 due to heavy rainfall, impacting agrochemical consumption. Despite this, H1 sales grew 9% YoY, & profit grew 11%. Q2 consolidated revenue was ₹930 Cr, slightly down YoY, with gross margins at 43.1%. H1 revenue reached ₹1,987 Cr.
- 03
- Hero MotoCorp reported strong performance during the festive season. The company recorded nearly 10 lakh retail registrations & over 6 lakh wholesale dispatches in Oct 2025. This reflects sustained festive momentum & increased customer confidence. Hero MotoCorp also expanded its global presence by entering European markets.
- 04
- Cipla Ltd. has entered into definitive agreements to acquire a 100% stake in Inzpera Healthsciences Ltd. for approximately ₹110.65 Cr. Inzpera, established in 2016, specializes in developing, manufacturing, & marketing paediatric pharmaceutical & wellness products. The acquisition is a strategic move to merge Inzpera's product range with Cipla's distribution network. The deal is expected to conclude within 1 month.
- 05

Gravita India Ltd's Q2 & H1 FY26 earnings call highlighted a steady performance. The company's expansion program is on track, with the current installed capacity at 3.40 lakh metric tons per annum. They aim to more than double this to over 7 lakh metric tons per annum by FY '28. The capex budget is approximately ₹1,225 Cr by FY '28.

### Stock for Investment

### **HDFC Life Insurance Company Ltd.**

Stock Symbol	HDFCLIFE
Sector	Life Insurance
*CMP (₹)	747
^Target Price (₹)	870
Upside	16.5%

- + HDFC Life is a leading private life insurer offering a diversified suite of protection, savings, annuity, and investment products with strong bancassurance and digital presence.
- + Q2FY26 net premium income rose 13.3% YoY to ₹18,777 cr, supported by robust first-year and renewal premiums; individual APE grew 8.7% YoY to ₹3,693 cr.
- + VNB margin remained steady at 24.1%, aided by a balanced mix of ULIP (37%), participating (25%), and protection (16%) products despite GST-related pressures.
- + The company added 50,000+ agents in H1FY26, expanding reach in tier 2/3 markets; bancassurance continued to contribute ~60% of APE with strong digital integration.
- + We forecast APE/VNB/PAT CAGR of 12%/18%/20% over FY25-27E and maintain a Buy rating with a target price of ₹870 (2.6× FY27E EV)

<sup>\*</sup>CMP as on November 03, 2025 ^Time horizon - upto 11 Months





## **Technical**

### Seeing rebound but consolidation is still on. Stay stock-specific.

NIFTY	S1	\$2	R1	R2
25763.35 <b>7</b> 41.25 (0.16%)	25600	25500	25850	26000



- + Nifty held steady on Monday, with the Nifty 50 closing nearly flat at 25,763.35, up 0.13%, indicating continued consolidation after a strong October rally.
- + The index opened on a subdued note and remained range-bound throughout the session amid mixed global cues.
- + Technically, Nifty is expected to see further consolidation, with critical support placed around 25,600.
- + Amid this setup, we continue to recommend a selective approach, focusing on sectors showing relative strength, and preferring large-cap and large mid-cap stocks for long trades while maintaining moderate position sizes amid global uncertainty.

BANKNIFTY	SI	<b>S2</b>	R1	R2
58101.45 <b>7</b> 325.10 (0.56%)	57700	57450	58300	58600



- The banking index recovered after two consecutive declines, preserving its broadly positive tone.
- + It continues to trade above key moving averages, forming a stable base while consolidating within a narrow sideways range in recent sessions.
- + With the exception of AU Bank, all other constituents ended in positive territory, led by Bankbaroda, Canbk and SBIN.
- From a technical standpoint, the index encounters immediate resistance near 58,600, while support is positioned around the 57,450 zone, reinforcing overall structural strength.





### **Technical**

Stock of the day	Recom.	CMP (₹)	Range*	SL	Target
LUPIN	BUY	1983.80	1980-1985	1915	2120



- The stock is exhibiting renewed strength as prices move above key short-term averages alongside rising volumes, indicating active accumulation.
- The emerging pattern of higher lows reflects effective downside absorption and strengthening upward momentum.
- With prices closing firmly above 20, 50 and 100 EMAs and momentum conditions are also improving, selling pressure appears to be easing.
- Traders may evaluate long opportunities near current levels to align with the prevailing bullish structure and capitalize on the developing positive trend.

"	1141110
Momentum Stocks Midcap	SWSOLAR
	EQUITASBNK
	MEDPLUS
	PRSMJOHNS
	ZENSARTECH

Name	Price	Price %
SWSOLAR	237.80	8.137
EQUITASBNK	60.99	7.027
MEDPLUS	815.00	6.847
PRSMJOHNSN	144.10	5.15¥
ZENSARTECH	754.80	5.36 🗵

Name	Price	Price %	_
PHOENIXLTD	1750.00	4.017	Rang
LODHA	1236.40	3.217	ge B reak
TORNTPOWER	1343.00	2.017	Breako akdown
ADANIENT	2469.50	لا0.46	J. (c)
AMBER	7946.00	لا1.13	

Top 5 F&O Gainers 7	Name	Price	Price %
	IDEA	9.58	9.747
	SHRIRAMFIN	795.15	6.187
	HFCL	77.99	6.097
	GODREJCP	1179.90	5.487
	INDUSTOWER	382.75	5.277

Name	Price	Price %	Тор
PATANJALI	575.00	4.55كا	<del>Ö</del> 5
MARUTI	15634.00	3.41ك	F&O
ADANIGREEN	1108.00	2.81ك	
PAYTM	1274.00	2.24🛭	Losers
BLUESTARCO	1905.60	1.644	K

Bullish Charts	Name	Price	Price %
	BANKBARODA	291.40	4.677
	IDEA	9.58	9.747
	LTF	279.90	3.487
	PHOENIXLTD	1750.00	4.017
	VEDL	512.70	3.887

Name	Price	Price %	
ITC	414.00	ובו5.1	
NAUKRI	1360.00	لا33.1	
PAGEIND	40645.00	1.354	
TCS	3019.50	الا 1.26	
VOLTAS	1369.60	1.012	





# **Research Team**

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Rajan Gupta	rajan.gupta1@religare.com
Vivek Chandra	vivek.chandra@religare.com
Himanshu Gupta	himanshu.gupta1@religare.com
Vishvajeet Singh	vishvajeet.singh1@religare.com





# **Disclaimer**

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <a href="https://www.religareonline.com/disclaimer">https://www.religareonline.com/disclaimer</a>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation—Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement		Answer	
		Yes	No	
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No	
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No	
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No	
	I/we have received any compensation from the subject company in the past twelve months?		No	
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No	
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No	
	I/we have served as an officer, director or employee of the subject company?		No	
	I/we have been engaged in market making activity for the subject company?		No	

Nature of Interest if answer to F(a) above is Yes:	Name(s) with Signature(s) of RA(s)

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results



















